Cambrex has acquired IEP GmbH to expand its biocatalytic process development services and the range of enzymes it can offer to pharma clients.
Germany-based IEP has a portfolio of more than 100 proprietary enzymes which have been used in numerous commercialised processes, according to Cambrex.
These include tools to perform a “green” biocatalytic step in chemical synthesis. Using this method IEP can cost effectively produce enantiomerically pure chemical products and intermediates at commercial scale.
IEP will continue to operate at its site in Wiesbaden, Germany and will be remained Cambrex IEP. Financial details of the deal have not been disclosed.